State Street Holds 5% Of Vanda Without Seeking To Influence Its Control
The position covers 3,010,531 common shares, with shared voting authority over 2,938,155 shares.
State Street reported a 5% passive stake in Vanda Pharmaceuticals, which develops and sells prescription drugs, in an SEC ownership disclosure filed Tuesday. The position covers 3,010,531 common shares, and State Street certified that the holding was not intended to change or influence Vanda's control.
Voting Authority Covers Fewer Shares
State Street's reported position is dated September 30, 2026. Its 5% figure measures ownership of Vanda's common-stock class under the disclosure's beneficial-ownership rules.
State Street listed shared voting authority over 2,938,155 shares and shared authority to dispose of all 3,010,531 shares. It listed zero shares under sole voting or sole disposal authority.
The certification describes the securities as bought and held through ordinary business activity, rather than as part of an effort or transaction to influence control.
Vanda's Prescription-Drug Business
Washington, D.C.-based Vanda sells Fanapt for schizophrenia and manic or mixed episodes of bipolar I disorder; HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep problems associated with Smith-Magenis syndrome; and PONVORY for relapsing forms of multiple sclerosis.
In 2025, Fanapt sales totaled $117.3 million, HETLIOZ sales were $71.4 million and PONVORY sales reached $27.4 million. Most sales came from the United States, with some in Israel, Europe and Canada.
Vanda's commercial lineup also includes NEREUS, approved in December 2025 to prevent vomiting caused by motion. The company is developing additional drugs and new uses for existing products.
Vanda had a market value of $247 million in Tuesday trading as of 9:39 a.m. ET.